INJECTIBLE Hypoglycemic Drugs GLP-1 Analogs Exenatide ER Trade Names: Byetta (daily) Bydureon (weekly - extended release) Generic (Nov 2024) Drug Class: DPP-IV resistant Incretin (GLP-1 like) Mimetic Mechanism of Action: a synthetic analog of glucagon-like-polypeptide 1 (GLP-1) that is resistant to breakdown by DPP-IV
Glucose-6-phosphate dehydrogenase (G6PD)-deficient infants: enzyme activity and gene variants as risk factors for phototherapy in the first week of life
During your consultation, we will review your medical history, discuss your goals, and create a plan tailored just for you
The hard numbers come from thymosin beta-4, the parent molecule of TB-500
Less rigorous than a prospective randomised trial but useful for generating preliminary evidence
Regulatory Timeline and Expectations CagriSema (Cagrilintide + Semaglutide): FDA review ongoing for obesity indication European Medicines Agency (EMA) submission completed Potential approval expected in late 2026 or early 2027 Would represent first approved amylin analogue combination therapy Cagrilintide Monotherapy: Less likely to be pursued as standalone therapy Combination approaches show superior efficacy May remain primarily a research tool Emerging Research Questions Key questions driving current research include: Optimal combination partners Beyond semaglutide, which peptides pair best with cagrilintide
